Kentucky became the latest state to adopt Cannabidiol (CBD ) specific legislation today with the signing of their bill into law, joining both Utah and South Carolina who have also passed similar laws within the last 30 days. The fact that these bills were able to be pushed thru so quickly, speaks volumes to the growing awareness of Cannabidiol (CBD) and the significant impact it is having in the experimental treatment of a myriad of illnesses, many of them afflicting children.
These laws also serve to point out the glaring ongoing injustice that is the continued designation of Cannabis as a Schedule 1 substance with “no acceptable medical use”. With the plant cleared by state laws for medical use in almost half of the country and hundreds of thousands of patients on the various state registries that in turn required thousands and thousands of individual physician recommendations, the notion that the Cannabis plant is devoid of any acceptable medical use is archaic and patently absurd at this point.
The focus on CBD is a good one in that it effectively erodes the myth of a lack of medicinal value in Cannabis, but dangers could lie in focusing in too deeply on one particular cannabinoid when the whole story of Cannabis as medicine is much more compelling, with dozens of Cannabiniods that still need to be properly researched. While these are certainly tiny victories in the overall battle, the basic fact remains that this is a healing plant that everyone should be able to legally grow and benefit from and the laws need to ultimately change to reflect that. We cannot end up with a situation where big pharma and big business, big Marijuana as it were, are the only sanctioned distributors of this substance, an herb that can be grown at home with minimal effort, in the same way you would grow sage in your garden.
These laws allow research programs to begin to open up in the states that adopt them, as well as force the Fed to contend with the question of whether it will supply these programs from the federal pot farm at UMiss and these will mark important changes as virtually Zero funded research is able to be done on Cannabis in the U.S. at the moment. With several states now passing similar bills, the real question of where the Cannabis to be used in these programs is going to come from will have to be addressed.
In the meantime, this is great news for the patients that will initially be approved by these first well intentioned, if not clumsily implemented programs and they will help pave the way for patients in other states. That they will be able to participate in active study programs is also an exciting prospect for U.S. research into medicinal Cannabis applications. It is good to see, that with enough outcry and public support, legislation like this can be expeditiously passed for those that are suffering and in real need.